jueves, 15 de febrero de 2018

FDA approves new treatment for prostate cancer using novel clinical trial endpoint - Drug Information Update

The Division of Drug Information (DDI) - serving the public by providing information on human drug products and drug product regulation by FDA
The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Common side effects of Erleada include fatigue, high blood pressure (hypertension), rash, diarrhea, nausea, weight loss, joint pain (arthralgia), falls, hot flush, decreased appetite, fractures and swelling in the limbs (peripheral edema).

Severe side effects of Erleada include falls, fractures and seizures.

For more information, please visit: Erleada

No hay comentarios: